These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 22333315)

  • 1. Modulation of CXCR3 ligand secretion by prostaglandin E2 and cyclooxygenase inhibitors in human breast cancer.
    Bronger H; Kraeft S; Schwarz-Boeger U; Cerny C; Stöckel A; Avril S; Kiechle M; Schmitt M
    Breast Cancer Res; 2012 Feb; 14(1):R30. PubMed ID: 22333315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer.
    Bronger H; Singer J; Windmüller C; Reuning U; Zech D; Delbridge C; Dorn J; Kiechle M; Schmalfeldt B; Schmitt M; Avril S
    Br J Cancer; 2016 Aug; 115(5):553-63. PubMed ID: 27490802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferons induce CXCR3-cognate chemokine production by human metastatic melanoma.
    Dengel LT; Norrod AG; Gregory BL; Clancy-Thompson E; Burdick MD; Strieter RM; Slingluff CL; Mullins DW
    J Immunother; 2010; 33(9):965-74. PubMed ID: 20948440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heparins modulate the IFN-γ-induced production of chemokines in human breast cancer cells.
    Fluhr H; Seitz T; Zygmunt M
    Breast Cancer Res Treat; 2013 Jan; 137(1):109-18. PubMed ID: 23160925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclooxygenase inhibitors modulate NK activities that control metastatic disease.
    Kundu N; Walser TC; Ma X; Fulton AM
    Cancer Immunol Immunother; 2005 Oct; 54(10):981-7. PubMed ID: 15891886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10.
    Bergamaschi C; Pandit H; Nagy BA; Stellas D; Jensen SM; Bear J; Cam M; Valentin A; Fox BA; Felber BK; Pavlakis GN
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adenovirus type 5 E1A-induced apoptosis in COX-2-overexpressing breast cancer cells.
    Sugimoto T; Bartholomeusz C; Tari AM; Ueno NT
    Breast Cancer Res; 2007; 9(4):R41. PubMed ID: 17612393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemokine monokine induced by IFN-gamma/CXC chemokine ligand 9 stimulates T lymphocyte proliferation and effector cytokine production.
    Whiting D; Hsieh G; Yun JJ; Banerji A; Yao W; Fishbein MC; Belperio J; Strieter RM; Bonavida B; Ardehali A
    J Immunol; 2004 Jun; 172(12):7417-24. PubMed ID: 15187119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of prostaglandin E2 receptors in migration of murine and human breast cancer cells.
    Timoshenko AV; Xu G; Chakrabarti S; Lala PK; Chakraborty C
    Exp Cell Res; 2003 Oct; 289(2):265-74. PubMed ID: 14499627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CXCR3 Ligands in Cancer and Autoimmunity, Chemoattraction of Effector T Cells, and Beyond.
    Karin N
    Front Immunol; 2020; 11():976. PubMed ID: 32547545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors.
    Zweifel BS; Davis TW; Ornberg RL; Masferrer JL
    Cancer Res; 2002 Nov; 62(22):6706-11. PubMed ID: 12438270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TNFα-exposed bone marrow-derived mesenchymal stem cells promote locomotion of MDA-MB-231 breast cancer cells through transcriptional activation of CXCR3 ligand chemokines.
    Shin SY; Nam JS; Lim Y; Lee YH
    J Biol Chem; 2010 Oct; 285(40):30731-40. PubMed ID: 20650898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells.
    Basu GD; Pathangey LB; Tinder TL; Gendler SJ; Mukherjee P
    Breast Cancer Res; 2005; 7(4):R422-35. PubMed ID: 15987447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-27 and IFNγ regulate the expression of CXCL9, CXCL10, and CXCL11 in hepatitis.
    Basset L; Chevalier S; Danger Y; Arshad MI; Piquet-Pellorce C; Gascan H; Samson M
    J Mol Med (Berl); 2015 Dec; 93(12):1355-67. PubMed ID: 26199110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroprotective effects of cyclooxygenase-2 inhibitor celecoxib against toxicity of LPS-stimulated macrophages toward motor neurons.
    Huang Y; Liu J; Wang LZ; Zhang WY; Zhu XZ
    Acta Pharmacol Sin; 2005 Aug; 26(8):952-8. PubMed ID: 16038627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of angiotensin II activity enhanced the antitumor effect of cyclooxygenase-2 inhibitors via insulin-like growth factor I receptor pathway.
    Yasumaru M; Tsuji S; Tsujii M; Irie T; Komori M; Kimura A; Nishida T; Kakiuchi Y; Kawai N; Murata H; Horimoto M; Sasaki Y; Hayashi N; Kawano S; Hori M
    Cancer Res; 2003 Oct; 63(20):6726-34. PubMed ID: 14583467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of CXCR3 and its ligands expression in Brucellar spondylitis.
    Hu X; Shang X; Wang L; Fan J; Wang Y; Lv J; Nazierhan S; Wang H; Wang J; Ma X
    BMC Immunol; 2020 Nov; 21(1):59. PubMed ID: 33208100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CXC chemokine ligand (CXCL) 9 and CXCL10 are antagonistic costimulation molecules during the priming of alloreactive T cell effectors.
    Rosenblum JM; Shimoda N; Schenk AD; Zhang H; Kish DD; Keslar K; Farber JM; Fairchild RL
    J Immunol; 2010 Apr; 184(7):3450-60. PubMed ID: 20194716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression and regulation of the CXCL9-11 chemokines and CXCR3 receptor in Atlantic salmon
    Valdés N; Espinoza D; Pareja-Barrueto C; Olate N; Barraza-Rojas F; Benavides-Larenas A; Cortés M; Imarai M
    Front Immunol; 2024; 15():1455457. PubMed ID: 39301034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis.
    Rozic JG; Chakraborty C; Lala PK
    Int J Cancer; 2001 Aug; 93(4):497-506. PubMed ID: 11477553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.